Foundayo Pill: Uses, Dosage and Side Effects

Foundayo is a combined oral contraceptive pill prescribed to prevent pregnancy in women of reproductive age. Containing two synthetic hormones, ethinylestradiol and drospirenone, it is licensed by the MHRA for use in the UK and available on prescription. Like other combined oral contraceptives, it may also be considered for managing acne, heavy periods, or premenstrual symptoms. This article explains what Foundayo is, how it works, how to take it correctly, and what side effects to be aware of, helping you make an informed decision in discussion with your prescriber or pharmacist.

What is Foundayo and what is it used for?

Foundayo is an MHRA-licensed combined oral contraceptive containing ethinylestradiol and drospirenone, used primarily to prevent pregnancy and sometimes to manage acne or painful periods.

IMPORTANT EDITORIAL NOTICE: This article cannot be published in its current form.

The product identity of Foundayo has not been confirmed against the MHRA medicines register or the Electronic Medicines Compendium (emc) prior to this revision. The available evidence indicates that Foundayo is the UK brand name for orforglipron, a medicine licensed for weight management, and is not a combined oral contraceptive (COC) containing ethinylestradiol and drospirenone as the original draft assumed. All clinical content in this article is therefore misaligned with the actual product and must not be published.

This article must be withheld from publication until the following steps have been completed by a qualified editor or clinician:

1. Confirm the product identity of Foundayo on the MHRA medicines register and the emc, including the active ingredient(s), licensed indication(s), product licence (PL) number, and the relevant SmPC and patient information leaflet (PIL).

2. If Foundayo is confirmed to be orforglipron (or any other non-contraceptive medicine), the entire article must be replaced with content written specifically for that product, aligned to its confirmed UK SmPC and PIL, covering the correct mechanism of action, licensed indication(s), dosing, contraindications, warnings, interactions, and side effects. Relevant sources will include the emc SmPC and PIL, the MHRA Public Assessment Report, the EMA EPAR if applicable, any published NICE technology appraisal or guidance, and the BNF monograph when available.

3. If the original intent was to produce an article about a combined oral contraceptive containing ethinylestradiol and drospirenone, the article must be retitled to a confirmed UK brand name for that combination (for example, Yasmin, Lucette, or Yacella, subject to verification on the emc), and all clinical content must be aligned to that product's confirmed SmPC and PIL, together with current Faculty of Sexual and Reproductive Healthcare (FSRH) guidance on combined hormonal contraception.

4. No clinical content from this draft should be carried forward until the product identity has been confirmed, because the clinical information for a combined oral contraceptive and for a weight-management medicine are entirely different and the current content could cause patient harm if read in the context of the wrong product.

5. On rewrite, the heading and keyword should be reviewed to reduce the risk of the word "pill" being misread as a reference to a contraceptive pill, which is the common UK usage of that term. A title such as "Foundayo (orforglipron) tablets" would reduce this risk.

6. All references currently cited relate to combined oral contraception and do not support any statements about Foundayo or orforglipron. The reference list must be replaced in full with product-specific UK primary sources: emc SmPC, emc PIL, MHRA medicines register entry and PL number, MHRA Public Assessment Report where available, EMA EPAR if applicable, NICE guidance or technology appraisal if available, and BNF monograph when available.

The sections below are retained solely to document the content that was present before this review. They must not be read as accurate or applicable to any named product until the steps above have been completed.

How do you take Foundayo and what is the usual dose?

One tablet is taken daily for 21 consecutive days, followed by a seven-day tablet-free interval; it must be taken at the same time each day to maintain contraceptive effectiveness.

PUBLICATION BLOCKED: See the notice in the first section.

All dosing and regimen information in this section was written on the assumption that Foundayo is a combined oral contraceptive containing ethinylestradiol and drospirenone. This assumption has not been confirmed and is contradicted by the available evidence, which indicates Foundayo is the UK brand name for orforglipron, a weight-management medicine. The dosing information below does not apply to orforglipron and must not be published.

Once the product identity has been confirmed against the MHRA register and the relevant emc SmPC, this section must be rewritten to reflect the correct posology and administration instructions for the confirmed product. For orforglipron, this will include: initiation and titration schedule per SmPC section 4.2; administration instructions (for example, timing in relation to food and drink, and swallowing instructions); missed-dose guidance; advice on what to do following vomiting or diarrhoea; dose adjustments or groups in whom the medicine is not recommended (including renal or hepatic impairment and older adults); and a summary of clinically relevant drug interactions per SmPC section 4.5 and the BNF.

If the confirmed product is a combined oral contraceptive, the rewrite must be aligned to the confirmed product SmPC (sections 4.2 and 4.5) and to current FSRH guidance on combined hormonal contraception, including FSRH CEU missed-pill guidance and emergency contraception guidance.

The content below is retained for documentation purposes only and must not be published.

What are the side effects of Foundayo and when should I get help?

Common side effects include nausea, headache, and irregular bleeding; seek emergency help immediately for chest pain, difficulty breathing, leg swelling, or sudden neurological symptoms, which may indicate a blood clot or stroke.

PUBLICATION BLOCKED: See the notice in the first section.

All side effect information in this section was written on the assumption that Foundayo is a combined oral contraceptive containing ethinylestradiol and drospirenone. This assumption has not been confirmed and is contradicted by the available evidence. The side effect profile of a combined oral contraceptive, including venous thromboembolism risk, arterial thromboembolism risk, and drospirenone-related potassium effects, does not apply to orforglipron and must not be published in the context of that product.

Once the product identity has been confirmed, this section must be rewritten to reflect the correct adverse reaction profile, contraindications, warnings, and monitoring requirements for the confirmed product, aligned to the confirmed SmPC (sections 4.3, 4.4, 4.6, and 4.8) and relevant UK clinical guidance. The rewrite should: present adverse reactions by frequency and system organ class; include clear red-flag actions describing when to seek urgent medical help, aligned to the SmPC, PIL, and NHS style; cover contraindications (SmPC 4.3), special warnings and precautions (SmPC 4.4), and pregnancy and breastfeeding advice (SmPC 4.6); and avoid minimising serious risks (for example, if pancreatitis is listed in the SmPC, it must not be described as a small risk unless the SmPC quantifies it in those terms). All safety statements must be aligned to the UK SmPC and must not import US-only warnings or contraindications.

Once this section has been rewritten for the confirmed product, it should include a single statement advising patients and healthcare professionals to report suspected side effects to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

The content below is retained for documentation purposes only and must not be published.

How does Foundayo work in the body?

Foundayo suppresses ovulation by inhibiting FSH and LH release, thickens cervical mucus, and alters the endometrium, providing three complementary mechanisms of contraceptive protection.

PUBLICATION BLOCKED: See the notice in the first section.

The mechanism of action described in the original draft applies to a combined oral contraceptive containing ethinylestradiol and drospirenone. This does not apply to orforglipron, which the available evidence indicates is the confirmed identity of Foundayo. Orforglipron is an oral non-peptide GLP-1 receptor agonist; its mechanism of action, pharmacology, and class-related risks are entirely different from those of a combined oral contraceptive.

Once the product identity has been confirmed against the MHRA register and the relevant emc SmPC, this section must be rewritten to describe the correct mechanism of action for the confirmed product in language appropriate for a patient-facing audience. For orforglipron, relevant sources will include the pharmacodynamic and pharmacokinetic sections of the emc SmPC (sections 5.1 and 5.2), the EMA EPAR if applicable, and the MHRA Public Assessment Report where available. The rewrite should briefly relate the mechanism to common adverse effects and relevant counselling points where this is helpful for patients, without promotional language. If efficacy data are included, they must be attributed to named Phase 3 trials with appropriate context; cross-trial comparisons should be avoided, and the evidence base should be date-checked to prevent reliance on superseded data.

The content below is retained for documentation purposes only and must not be published.

Scientific References

1. Ethinylestradiol with drospirenone | Drugs – BNF – NICE.
2. Combined hormonal contraceptives and venous thromboembolism: review confirms risk is small.
3. The Yellow Card scheme: guidance for healthcare professionals, patients and the public.
4. St John's wort: interaction with hormonal contraceptives, including implants.
5. Contraceptives, interactions | Treatment summaries – BNF – NICE.
6. Contraceptives, hormonal | Treatment summaries – BNF – NICE.
7. Adverse reactions to drugs | Medicines guidance – BNF – NICE.
8. Side effects and risks of the combined pill – NHS.UK.
9. Rivera R et al. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999..
10. Hall SD et al. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther. 2003..
11. Sitruk-Ware R et al. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas. 2006..
12. White WB et al. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005..
13. Gomes Rezende M et al. Exploring Antibiotic-Mediated Disruption of Enterohepatic Circulation and Combined Oral Contraceptive Efficacy: A Systematic Review. Womens Health Rep (New Rochelle). 2025..
14. Stegeman BH et al. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf. 2013..

Frequently Asked Questions